Key Takeaways
- Revenue jumps ₹100 Cr in a single quarter: Net revenue grew 28% YoY to ~₹450 Cr, driven by all four segments, with API exports to the US and a formulation turnaround leading the charge.
- EBITDA margin doubles as operating leverage kicks in: Margins expanded from 6.22% to 12.18% because most expenses are fixed; management says it has "cracked" the profitability puzzle.
- Formulation emerges as the third growth engine: A 40% surge this quarter, powered by a tripling of capsule tableting capacity and the start of Jan Aushadhi generic supplies, sets the stage for a ₹500 Cr business within three years.
- The balance sheet is debt-free, so profits convert directly: PAT rose 256% to ₹32 Cr, and management sees a path to double-digit PAT margins by FY2026.
- What to watch next quarter: Whether the new formulation capacity, now fully operational, delivers the promised 60% growth, and if the 20-30 bps quarterly EBITDA uplift materializes.
The Profitability Inflection
- The "cracking it" moment: Management had been struggling to lift EBITDA until this quarter, when revenue growth flowed directly to the bottom line because the cost base is overwhelmingly fixed. The result was a near-doubling of the EBITDA margin in a single quarter.
- Scale is reshaping unit economics: In formulation, the salary percentage of the plant dropped from 27-28% to 15-16% simply because production doubled, a dynamic management expects to continue as new capacity ramps up.
- Blended margin ambition: The company aims to add 20 to 30 basis points every quarter, targeting a regular blended EBITDA of 12% to 13% over the coming two years, with year-by-year additions of 150 to 200 basis points.
- PAT trajectory: Management expects PAT margins around 6% by the end of this fiscal year, with a path to double digits in FY2026, supported by the debt-free balance sheet.
Suri: "This is one area which the company was lacking and struggling and trying to find ways how do we increase our EBITDA and certainly the pressure was to increase our revenues on the gross because most of the expenses are fixed expenses, so we have been able to crack it."
API: The Export Engine Shifts Gears
- Exports drive the 20% API growth: While domestic API grew only 1%, exports surged 31%, led by supplies to US regulated markets. US market share in API rose 5 percentage points to 17.9%.
- Fexofenadine (Allegra) is the star molecule: USFDA approval received during COVID has now translated into commercial supplies, with the product posting 180% growth. Other key products also performed: Rosuvastatin up 80%, Atorvastatin up 15%, Montelukast up 20%.
- Volume is surging even as prices soften: Quantity produced rose 37% (nearly 40%) due to capacity additions, but sales prices have declined. Management notes China prices have softened, enabling better vendor negotiations.
- Capacity expansion is non-negotiable: The company started the year with 310 KL capacity and is closing near 400 KL, having added roughly 90 KL. Without this, it could not have serviced the market. A further 100 KL addition is planned over the next six to nine months, funded from internal accruals.
- Customer diversification is extreme: 55 new customers were added globally, including entry into two new countries. One European customer grew nearly 1000% (10X), while some smaller customers grew 200%.
Suri: "We started the year we have 310 Kilolitre capacity, but we are closing the year with almost 400 KL capacity so we have added almost 90 Kilolitre of capacity, which is showing up in our increase in the revenue."
Formulation: The Third Pillar Takes Shape
- From laggard to growth leader: A business that was previously growing at 2-5% delivered 40% growth in Q3, driven by a tripling of capsule tableting capacity from 3 Cr to 9 Cr per month. Management expects 60% growth next quarter as the new capacity becomes fully operational.
- Institutional business is the catalyst: While the branded business grew 7%, the institutional segment (Jan Aushadhi) surged 196%, and generics rose 15%. The company has also expanded its branded footprint with new headquarters in Hyderabad and Chennai.
- Margin profile is a work in progress: Gross margins in formulation currently sit at 30-35%, depressed by the mix of generics and Jan Aushadhi supplies. Management expects this to improve as branded reach expands and scale builds, with the business targeting ₹500 Cr in three years from a current ~₹230-240 Cr base.
- The segment mix is shifting structurally: API's share of revenue is expected to decline from 60% to around 50% as medical devices and formulation grow faster, creating a more balanced three-pillar structure.
Suri: "In this quarter itself it has grown 40%, so next quarter it will grow almost 60%, so we are expecting that formulation business give or take one year here or there it will become Rs.500 Crores in the coming three years time."
Medical Devices & OTC: Steady Growth, Strategic Patience
- Medical devices are back on a high-growth trajectory: The segment grew 24% in Q3 and 37% over nine months, driven by glucometers and BP monitors. The glucometer business operates on a razor-and-blade model, with 1.12 crore meters installed generating recurring strip revenue.
- BP monitors are a material contributor: Nine-month revenue reached ₹64 Cr, with a slight price increase taken in both BP monitors and glucometers. The company has been investing in backward integration, including a chip packaging unit, after depending on imports during COVID.
- Dr. Morepen OTC is being conserved, not abandoned: The business is undergoing a cleaning exercise, down 3% in Q3, as management deliberately reduces investment in the capital-intensive online channel. The long-term vision is to spin it out: management believes the brand "deserves its own IPO and its own freedom" once corporate-level issues are resolved.
- Cash conservation is the near-term strategy: Without an investor or strategic partner, the company is not investing in promotion or advertisement for OTC, having learned from a "bleeding exercise" during COVID when upfront customer acquisition costs consumed capital.
Suri: "Dr. Morepen is a consumers darling so it is basically a market friendly product so it deserves its own IPO and it deserves its own freedom but once we resolve things at a corporate level then Dr. Morepen will come out on its own, raise its own capital and go for its own IPO."
Capacity, Capex & the Balance Sheet
- API is running near full tilt: Capacity utilization is above 90-95%, which is optimal for a process industry. The planned addition of 250 KL over the next 12 months, plus further expansion depending on fundraising, is essential to sustain growth.
- Formulation capacity has headroom: The tripled capacity was not fully operational in Q3; Q4 should see it fully online, after which utilization will settle at 75-80% due to changeovers. This alone supports the near-term growth outlook.
- Capex is being funded internally for now: The immediate ₹125-150 Cr for API, ₹50 Cr for medical devices, and ₹40 Cr for formulation will come from internal accruals. Total capex plus working capital needs are estimated at ₹200-250 Cr over the next two to three years.
- The company is debt-free and open to leverage: Management is evaluating various options for resource augmentation, including debt, but no plan has been finalized. The debt-free status means almost all EBITDA currently flows to PAT.
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Blended EBITDA margin | Maintain 12-13% regularly, adding 20-30 bps per quarter | Coming two years |
| PAT margin | Reach ~6% by year-end, double digits thereafter | FY2026 |
| Formulation revenue | Grow to ₹500 Cr from ~₹230-240 Cr base | Three years |
| API capacity addition | Add 100 KL to current ~400 KL base | Six to nine months |
| Total API capacity addition | Add 250 KL | Next 12 months |
| Segment mix shift | API share to decline from 60% to ~50% | As devices and formulation outgrow |
| Capex + working capital outlay | ₹200-250 Cr | Next two to three years |
| Formulation growth | 60% growth next quarter | Q4 FY24 |
Key Metrics
| Metric | Q3 FY24 |
|---|---|
| Net revenue | ₹449 Cr, +28% YoY |
| EBITDA | ₹55 Cr, +151% YoY |
| EBITDA margin | 12.18%, vs 6.22% in Q3 FY23 |
| Profit before tax | ₹44 Cr, +200% YoY |
| Profit after tax | ₹32 Cr, +256% YoY |
| PAT margin | 7.13%, vs 2.57% in Q3 FY23 |
| EPS | ₹0.63, vs ₹0.18 in Q3 FY23 |
| API revenue | ₹253 Cr, +20% YoY |
| API exports growth | +31% YoY |
| Medical devices revenue growth | +24% YoY |
| Formulation business revenue growth | +40% YoY |
| OTC / Dr. Morepen revenue growth | -3% YoY |
| Institutional business (Jan Aushadhi) revenue | ₹32 Cr, +196% YoY |
| Glucometers installed base | 1.12 Cr meters |
| API capacity | ~400 KL, up from 310 KL at start of year |